Kahn Swick & Foti, LLC has launched an investigation into Sarepta Therapeutics following multiple patient deaths from acute liver failure linked to its gene therapy Elevidys, used to treat Duchenne muscular dystrophy. Despite Sarepta's initial assurances about the therapy's safety, three patients died between March and June 2025, leading to a securities class action lawsuit against the company and some executives for allegedly withholding material risk information. The investigation aims to determine if Sarepta's leadership breached fiduciary duties or violated laws. Investors with information or concerns are encouraged to contact the law firm for potential legal action.
Kessler Topaz Meltzer & Check LLP is investigating D-Wave Quantum Inc. for potential securities law violations following the company's disappointing Q2 2026 revenue of $3.08 million, which missed analyst expectations of around $4 million. The investi...
Optimism's OP token recovered after a roughly 12% drop on October 7, with open interest rising to about $107.82 million, up 17.25%. The positive funding rate of 0.0096% indicates stronger demand for long positions, though it also suggests potential r...
Ethereum (ETH) has bounced strongly off a key support level at $2,400 after a period of selling pressure and declining trading volumes, which have dropped by 58% to $5.2 billion, indicating reduced liquidity. Despite a recent $90 million hack of Ledg...
Worldcoin (WLD) is currently encountering resistance in its price between $0.56 and $0.75, which is a critical range for its market movement. Previously, WLD rallied to $0.4997 and ranked 56th by market capitalization. Analysts also highlight $1.0 as...
On October 10, 2025, Bitcoin's price plunged from around $122,000 to $105,000 within minutes, triggering nearly $19 billion in liquidations largely due to leveraged positions and derivatives. Despite improved tools for monitoring market risks, excess...
